Profound Medical Corp PROF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PROF is a good fit for your portfolio.
News
-
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
-
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
-
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
-
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
-
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
-
Profound Medical Shares Rise 8.7% After FDA Gives Clearance for TULSA-PRO Thermal Boost
Trading Information
- Previous Close Price
- $8.03
- Day Range
- $8.01–8.24
- 52-Week Range
- $7.11–15.49
- Bid/Ask
- $4.60 / $8.50
- Market Cap
- $196.16 Mil
- Volume/Avg
- 10,214 / 34,649
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 23.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 131
- Website
- https://www.profoundmedical.com
Comparables
Valuation
|
Metric
|
PROF
|
SWAV
|
LUNG
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 84.91 | — |
Price/Book Value | 5.48 | 18.26 | 2.37 |
Price/Sales | 23.51 | 17.27 | 4.03 |
Price/Cash Flow | — | 52.55 | — |
Price/Earnings
PROF
SWAV
LUNG
Financial Strength
|
Metric
|
PROF
|
SWAV
|
LUNG
|
|---|---|---|---|
Quick Ratio | 5.26 | 10.61 | 5.62 |
Current Ratio | 6.58 | 11.76 | 6.50 |
Interest Coverage | −38.40 | 26.24 | −19.37 |
Quick Ratio
PROF
SWAV
LUNG
Profitability
|
Metric
|
PROF
|
SWAV
|
LUNG
|
|---|---|---|---|
Return on Assets (Normalized) | −45.04% | 19.87% | −22.61% |
Return on Equity (Normalized) | −58.03% | 35.18% | −31.80% |
Return on Invested Capital (Normalized) | −50.48% | 22.54% | −25.75% |
Return on Assets
PROF
SWAV
LUNG
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Yvxtgcg | Fclrjx | $185.4 Bil | |
SYK
| Stryker Corp | Qjsyttgqp | Myk | $127.7 Bil | |
BSX
| Boston Scientific Corp | Crdrqtwn | Plmhv | $107.6 Bil | |
MDT
| Medtronic PLC | Sytdgkry | Rpshylp | $105.9 Bil | |
DXCM
| DexCom Inc | Czbghhph | Shknz | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Lfmwdymjs | Pjlpzj | $52.0 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Wbxzbnzyl | Xpzx | $24.6 Bil | |
ALGN
| Align Technology Inc | Xknzclb | Fvjqvr | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Mfbhkslhf | Cvfpr | $18.7 Bil | |
PODD
| Insulet Corp | Ffwghscfz | Vhjnb | $11.6 Bil |